Inflammatory response to cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 75, Issue 2, 2003, Pages

  Levy, Jerrold H ^a,b   Tanaka, Kenichi A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT; CYTOKINE; PROTEINASE; THROMBIN; THROMBOPLASTIN;

BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CELLULAR IMMUNITY; CONFERENCE PAPER; FIBRINOLYSIS; HEMOSTASIS; HUMORAL IMMUNITY; INFLAMMATION; MAST CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

APROTININ; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INTERLEUKINS; MAST CELLS; MYOCARDIAL REPERFUSION INJURY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBIN;

EID: 0037312501     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)04701-X     Document Type: Conference Paper

References (81)

1. Levy JH. Anaphylactic reactions in anesthesia and intensive care. 2nd ed. Stoneham: Butterworth-Heinemann, 1992.
2. Delves PJ, Roitt IM. Advances in immunology: the immune system. N Engl J Med 2000;343(Parts 1 and 2):37-49,108-17.
3. Kay AB. Advances in immunology: allergy and allergic diseases. N Engl J Med 2001;344:30-7.
4. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994;31:261-9.
5. Walport MJ. Advances in immunology: complement - first of two parts. N Engl J Med 2001;344:1058-66.
6. Walport MJ. Advances in immunology: complement - second of two parts. N Engl J Med 2001;344:1140-4.
7. Warltier DC, Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-52.
8. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002;30(Suppl):S302-12.
9. Mojcik C, Levy JH. Systemic inflammatory response syndrome and anti-inflammatory strategies. Ann Thorac Surg 2001;71:745-54.
10. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363-70.
11. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998;62:1817-24.
12. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
13. Grandaliano G, Valente AJ, Abboud HE. A novel biologic activity of thrombin. Stimulation of monocyte chemotactic protein production. J Exp Med 1994;179:1737-41.
14. Sower LE, Froelich CJ, Carney DH, Fenton JW, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 1995;155:895-901.
15. Bar-Shavit R, Kahn A, Mudd MD, Wilner GD, Mann KG, Fenton JW. Localization of a chemotactic domain in human thrombin. Biochemistry 1985;23:397.
16. Bar-Shavit R, Kahn A, Wilner G.D. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 1983;220:728.
17. Struova SM, Dugina TN, Khgatian SV, Redkozubov AE, Redkozuba GP, Pinelis VG. Thrombin-mediated events implicated in mast cell activation. Semin Throm Hemost 1996; 22:145.
18. ten Cate H, Schoenmakers SH, Franco R, et al. Microvascular coagulopathy and disseminated intravascular coagulation Crit Care Med 29(Suppl):S95-7.
19. Verrier ED, Boyle EM. Endothelial cell injury in cardiovascular surgery. Ann Thoracic Surg 1996;62:915-22.
20. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002;30(Suppl):S302-12.
21. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160:5130-5.
22. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol 1997;158:5435-41.
23. Nicholson AC, Nachman RL, Altieri DC, et al. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996;271:28407-13.
24. Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993;9:1-26.
25. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
26. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001;86:298-307.
27. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 2001;86:1353-9.
28. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79.
29. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-6.
30. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999;43:860-78.
31. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989;134:1087-97.
32. Levi M, de Jonge E, van der Poll T, ten Cate H. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Haemost 2001;27:569-75.
33. Boyle EM Jr, Canty TG Jr, Morgan EN, Yun W, Pohlman TH, Verrier ED. Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription. Ann Thorac Surg 1999;68:1949-53.
34. Levitsky J, Gurell D, Frishman WH. Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. J Clin Pharmacol 1998;38:887-97.
35. Hammon JW Jr, Vinten-Johansen J. Myocardial protection from surgical ischemic-reperfusion injury. Introduction. Ann Thorac Surg 1999;68:1897.
36. Déry O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998;274:C1429-52.
37. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
38. Sugama Y, Tiruppathi C, Offakidevi K, Andersen TT, Fenton JW II, Malik AB. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. J Cell Biol 1992;119:935-44.
39. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997;99:155.
40. Galli SJ, Wershil BK. The two faces of the mast cell. Nature 1996;381:21-2.
41. Tannenbaum S, Oertel H, Henderson W, Kaliner M. The biologic activity of mast cell granules. I. Elicitation of inflammatory responses. J Immunol 1980;125:325-35.
42. Kanwar S, Kubes P. Mast cells contribute to ischemia-reperfusion-induced granulocyte infiltration and intestinal dysfunction. Am J Physiol 1994;267:G316-21.
43. Enerback L. The differentiation and maturation of inflammatory cells involved in the allergic response: mast cells and basophils. Allergy 1997;52:4-10.
44. Valent P, Bettelheim P. The human basophil. Crit Rev Oncol Hematol 1990;10:327-52.
45. Costa JJ, Weller PF, Galli SJ. The cells of the allergic response: mast cells, basophils, and eosinophils. JAMA 1997; 278:1815-22.
46. Beaven MA, Metzger H. Signal transduction by Fc receptors. Immunol Today 1993;14:222-6.
47. Kinet J-P. The high-affinity receptor for IgE. Curr Opin Immunol 1989;2:499-505.
48. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-92.
49. Edmunds LH Jr. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998;66(Suppl):S12-6.
50. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002;34:1084-93.
51. Kalter RD, Saul CM, Wetstein L, et al. Cardiopulmonary bypass: associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979;77:427-35.
52. Zaidan JR, Johnson S, Brynes R, et al. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986;65:377-80.
53. Hashimoto K, Yamagishi M, Sasaki T, et al. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1995;58:799-805.
54. Levy JH, Despotis GJ, Szlam F, Olson PJ, Meeker DP, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose finding study. Anesthesiology 2002;96:1095-102.
55. Levy JH, Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin, production and role in cardiovascular disorders. Semin Thromb Hemost 2001;27:405-16.
56. Fitch JCK, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499-506.
57. Chaney MA. Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest 2002;121:921-31.
58. Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 56:928-36.
59. Levy JH, Pifarre R, Schaff H, et al. A multicenter, placebo-controlled, double-blind trial of aprotinin to reduce blood loss and the requirement of donor blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
60. Miller BE, Tosone SR, Tam VKH, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac surgery. Ann Thorac Surg 1998;66:535-40.
61. Alderman EL, Levy JH, Rich J, et al. International multicenter aprotinin graft patency experience (IMAGE). J Thorac Cardiovasc Surg 1998;116:716-30.
62. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001;72:2169-75.
63. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 2000;120:370-8.
64. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 2000; 120:361-9.
65. Asimakopoulos G, Lidington EA, Mason J, et al. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 2001;122:123-8.
66. Czerny M, Baumer H, Kilo J, et al. Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardio-thorac Surg 2000;17:737-42.
67. Ascione R, Lloyd CT, Underwood MJ, Lotto AA, Pitsis AA, Angelini GD. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 2000;69:1198-204.
68. Deng MC, Dasch B, Erren M, Möllhoff T, Scheld HH. Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. Ann Thorac Surg 1996;62:184-90.
69. Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg 1998;65:420-4.
70. Matata BM, Sosnowski AW, Galiñanes M. Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg 2000;69:785-91.
71. Gu YJ, Mariani MA, Boonstra PW, Grandjean JG, van Oeveren W. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. Chest 1999;116:892-8.
72. Strüber M, Cremer JT, Gohrbandt B, et al. Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass. Ann Thorac Surg 1999;68:1330-5.
73. Wan S, Izzat MB, Lee TW, Wan IYP, Tang NLS, Yim APC. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg 1999;68:52-7.
74. Diegeler A, Doll N, Rauch T, et al. Humoral immune response during coronary artery bypass grafting. A comparison of limited approach, "off-pump" technique, and conventional cardiopulmonary bypass. Circulation 2000; 102(Suppl 3):III95-100.
75. Menasche P. The systemic factor: the comparative roles of cardiopulmonary bypass and off-pump surgery in the genesis of patient injury during and following cardiac surgery. Ann Thorac Surg 2001;72:S2260-6.
76. Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W, Ebels T. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg 1999;67:1370-5.
77. Casati V, Gerli C, Franco A, et al. Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. Anesthesiology 2001;95:1103-9.
78. Englberger L, Markart P, Eckstein FS, Immer FF, Berdat, PA, Carrel TP. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur J Cardiothorac Surg 2002;22:545-51.
79. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002;359:1194-9.
80. Gu YJ, Mariani MA, Boonstra PW, Grandjean JG, van Oeveren W. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. Chest 1999;116:892-8.
81. Fransen E, Maessen J, Dentener M, Senden N, Geskes G, Buurman W. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998;113:1290-5.